CryptoCarl said:

Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

My labs after 12 months on glycaemic control: A1C 5.1%, fasting glucose 86 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.7% and fasting glucose was 111 mg/dL. The improvement has been dramatic and consistent.

BariatricNurseD said:

My labs after 12 months on glycaemic control: A1C 5.1%, fasting glucose 86 mg/dL, fasting insulin 5 uIU/mL.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 6.0 (insulin resistant) → Current = 1.0 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

CryptoCarl said:

Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

This matches mine closely enough to be worth saying so out loud.

From the other side of the consultation, briefly.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.